Механизмы развития инфекции мочевых путей и бессимптомной бактериурии
Механизмы развития инфекции мочевых путей и бессимптомной бактериурии
Захарова И.Н., Мумладзе Э.Б., Мачнева Е.Б., Касьянова А.Н. Механизмы развития инфекции мочевых путей и бессимптомной бактериурии. Педиатрия (Прил. к журн. Consilium Medicum). 2018; 1: 106–110.
DOI: 10.26442/2413-8460_2018.1.106-110
DOI: 10.26442/2413-8460_2018.1.106-110
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В обзорной статье приводятся современные данные о процессах, происходящих на поверхности эпителия мочевых путей при взаимодействии с микроорганизмами. Описаны три основных звена, отвечающих за формирование бессимптомной бактериурии и инфекции мочевых путей – особенности микроорганизма, особенности иммунного ответа организма на присутствие микроба в мочевых путях, а также особенности воздействия микро- и макроорганизма друг на друга. Особое внимание уделено данным о нормальном микробиоме мочи и его протективных свойствах.
Ключевые слова: бессимптомная бактериурия, микробиом мочи, вирулентность, уропатогенные штаммы, инфекция мочевых путей, цистит, пиелонефрит, кишечная палочка.
Key words: asymptomatic bacteriuria, urine microbiology, virulence, uropathogenic strains, urinary tract infection, cystitis, pyelonephritis, E. coli.
Ключевые слова: бессимптомная бактериурия, микробиом мочи, вирулентность, уропатогенные штаммы, инфекция мочевых путей, цистит, пиелонефрит, кишечная палочка.
________________________________________________
Key words: asymptomatic bacteriuria, urine microbiology, virulence, uropathogenic strains, urinary tract infection, cystitis, pyelonephritis, E. coli.
Список литературы
1. Russo TA, Johnson JR. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect 2003; 5 (5): 449–56.
2. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon 2003; 49 (2): 71–82.
3. Jones CH, Pinkner JS, Roth R et al. FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. Proc Natl Acad Sci USA 1995; 92 (6): 2081–5.
4. Zhou G, Mo WJ, Sebbel P et al. Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. J Cell Sci 2001; 114 (Pt. 22): 4095–103.
5. Xie B, Zhou G, Chan SY et al. Distinct glycan structures of uroplakins Ia and Ib: structural basis for the selective binding of FimH adhesin to uroplakin Ia. J Biol Chem 2006; 281 (21): 14644–53.
6. Martinez JJ, Mulvey MA, Schilling JD et al. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 2000; 19 (12): 2803–12.
7. Rosen DA, Pinkner JS, Walker JN et al. Molecular variations in Klebsiella pneumoniae and Escherichia coli FimH affect function and pathogenesis in the urinary tract. Infect Immun 2008; 76 (7): 3346–56.
8. Martinez JJ, Mulvey MA, Schilling JD et al. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 2000; 19 (12): 2803–12.
9. Dhakal BK, Mulvey MA. Uropathogenic Escherichia coli invades host cells via an HDAC6-modulated microtubule-dependent pathway. J Biol Chem 2009; 284 (1): 446–54.
10. Justice SS, Hung C, Theriot JA et al. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci USA 2004; 101 (5): 1333–8.
11. Rosen DA, Pinkner JS, Jones JM et al. Utilization of an intracellular bacterial community pathway in Klebsiella pneumoniae urinary tract infection and the effects of FimK on type 1 pilus expression. Infect Immun 2008; 76 (7): 3337–45.
12. Mysorekar IU, Hultgren SJ. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci USA 2006; 103 (38): 14170–5.
13. Kau AL, Martin SM, Lyon W et al. Enterococcus faecalis tropism for the kidneys in the urinary tract of C57BL/6J mice. Infect Immun 2005; 73 (4): 2461–8.
14. Kline KA, Ingersoll MA, Nielsen HV et al. Characterization of a novel murine model of Staphylococcus saprophyticus urinary tract infection reveals roles for Ssp and SdrI in virulence. Infect Immun 2010; 78 (5): 1943–51.
15. Nielubowicz GR, Mobley HL. Host-pathogen interactions in urinary tract infection. Nat Rev Urol 2010; 7 (8): 430–41.
16. Sobel JD, Fisher JF, Kauffman CA, Newman CA. Candida urinary tract infections – epidemiology. Clin Infect Dis 2011; 52 (Suppl. 6): S433–6.
17. Tsai PW, Yang CY, Chang HT, Lan CY. Human antimicrobial peptide LL-37 inhibits adhesion of Candida albicans by interacting with yeast cell-wall carbohydrates. PLoS One 2011; 6 (3): e17755.
18. Yin X, Hou T, Liu Y et al. Association of Toll-like receptor 4 gene polymorphism and expression with urinary tract infection types in adults. PLoS One 2010; 5 (12): e14223.
19. Fischer H, Yamamoto M, Akira S et al. Mechanism of pathogen-specific TLR4 activation in the mucosa: fimbriae, recognition receptors and adaptor protein selection. Eur J Immunol 2006; 36 (2): 267–77.
20. Ragnarsdоttir B, Fischer H, Godaly G et al. TLR- and CXCR1-dependent innate immunity: insights into the genetics of urinary tract infections. Eur J Clin Invest 2008; 38 (Suppl. 2): 12–20.
21. Ragnarsdóttir B, Samuelsson M, Gustafsson MC et al. Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria. J Infect Dis 2007; 196 (3): 475–84.
22. Wang H, Min G, Glockshuber R et al. Uropathogenic E. coli adhesin-induced host cell receptor conformational changes: implications in transmembrane signaling transduction. J Mol Biol 2009; 392 (2): 352–61.
23. Klumpp DJ, Rycyk MT, Chen MC et al. Uropathogenic Escherichia coli induces extrinsic and intrinsic cascades to initiate urothelial apoptosis. Infect Immun 2006; 74 (9): 5106–13.
24. Ingersoll MA, Kline KA, Nielsen HV, Hultgren SJ. G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity. Cell Microbiol 2008; 10 (12): 2568–78.
25. Dielubanza EJ, Schaeffer AJ. Urinary tract infections in women. Med Clin North Am 2011; 95 (1): 27–41.
26. Hannan TJ, Mysorekar IU, Hung CS et al. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 2010; 6 (8): e1001042.
27. Sivick KE, Mobley HL. Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect Immun 2010; 78 (2): 568–85.
28. Ingersoll MA, Albert ML. From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa. Mucosal Immunol 2013; 6 (6): 1041–53.
29. Fouts DE, Pieper R, Szpakowski S et al. Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury. J Transl Med 2012; 10: 174.
30. Siddiqui H, Nederbragt AJ, Lagesen K et al. Assessing diversity of the female urine microbiota by high throughput sequencing of 16S rDNA amplicons. BMC Microbiol 2011; 11: 244.
31. Sundén F, Hаkansson L, Ljunggren E, Wullt B. Bacterial interference-is deliberate colonization with Escherichia coli 83972 an alternative treatment for patients with recurrent urinary tract infection? Int J Antimicrob Agents 2006; 28 (Suppl. 1): S26–9.
32. Darouiche RO, Hull RA. Bacterial interference for prevention of urinary tract infection. Clin Infect Dis 2012; 55: 1400–7.
33. Zdziarski J, Brzuszkiewicz E, Wullt B et al. Host Imprints on Bacterial Genomes-Rapid, Divergent Evolution in Individual Patients. PLoS Pathog 2010; 6 (8).
34. Naber KG, Kogan M, Wagenlehner FME et al. How the microbiome is influenced by the therapy of urological diseases: standard versus alternative approaches. Clin Phytoscience 2017; 3: 8.
35. Ivanov D, Abramov-Sommariva D, Moritz K et al. An open label, non-controlled, multicentre, interventional trial to investigate the safety and efficacy of Canephron® N in the management of uncomplicated urinary tract infections (uUTIs). Clin Phytoscience 2015; 1: 7.
36. Gessner A. The influence of urologic therapeutics on the microbiome in an experimental model” in “How the microbiome is influenced by the therapy of urological diseases: standard vs. alternative approaches”. Munich: 31st Annual EAU Congress; 2016.
2. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon 2003; 49 (2): 71–82.
3. Jones CH, Pinkner JS, Roth R et al. FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. Proc Natl Acad Sci USA 1995; 92 (6): 2081–5.
4. Zhou G, Mo WJ, Sebbel P et al. Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. J Cell Sci 2001; 114 (Pt. 22): 4095–103.
5. Xie B, Zhou G, Chan SY et al. Distinct glycan structures of uroplakins Ia and Ib: structural basis for the selective binding of FimH adhesin to uroplakin Ia. J Biol Chem 2006; 281 (21): 14644–53.
6. Martinez JJ, Mulvey MA, Schilling JD et al. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 2000; 19 (12): 2803–12.
7. Rosen DA, Pinkner JS, Walker JN et al. Molecular variations in Klebsiella pneumoniae and Escherichia coli FimH affect function and pathogenesis in the urinary tract. Infect Immun 2008; 76 (7): 3346–56.
8. Martinez JJ, Mulvey MA, Schilling JD et al. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 2000; 19 (12): 2803–12.
9. Dhakal BK, Mulvey MA. Uropathogenic Escherichia coli invades host cells via an HDAC6-modulated microtubule-dependent pathway. J Biol Chem 2009; 284 (1): 446–54.
10. Justice SS, Hung C, Theriot JA et al. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci USA 2004; 101 (5): 1333–8.
11. Rosen DA, Pinkner JS, Jones JM et al. Utilization of an intracellular bacterial community pathway in Klebsiella pneumoniae urinary tract infection and the effects of FimK on type 1 pilus expression. Infect Immun 2008; 76 (7): 3337–45.
12. Mysorekar IU, Hultgren SJ. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci USA 2006; 103 (38): 14170–5.
13. Kau AL, Martin SM, Lyon W et al. Enterococcus faecalis tropism for the kidneys in the urinary tract of C57BL/6J mice. Infect Immun 2005; 73 (4): 2461–8.
14. Kline KA, Ingersoll MA, Nielsen HV et al. Characterization of a novel murine model of Staphylococcus saprophyticus urinary tract infection reveals roles for Ssp and SdrI in virulence. Infect Immun 2010; 78 (5): 1943–51.
15. Nielubowicz GR, Mobley HL. Host-pathogen interactions in urinary tract infection. Nat Rev Urol 2010; 7 (8): 430–41.
16. Sobel JD, Fisher JF, Kauffman CA, Newman CA. Candida urinary tract infections – epidemiology. Clin Infect Dis 2011; 52 (Suppl. 6): S433–6.
17. Tsai PW, Yang CY, Chang HT, Lan CY. Human antimicrobial peptide LL-37 inhibits adhesion of Candida albicans by interacting with yeast cell-wall carbohydrates. PLoS One 2011; 6 (3): e17755.
18. Yin X, Hou T, Liu Y et al. Association of Toll-like receptor 4 gene polymorphism and expression with urinary tract infection types in adults. PLoS One 2010; 5 (12): e14223.
19. Fischer H, Yamamoto M, Akira S et al. Mechanism of pathogen-specific TLR4 activation in the mucosa: fimbriae, recognition receptors and adaptor protein selection. Eur J Immunol 2006; 36 (2): 267–77.
20. Ragnarsdоttir B, Fischer H, Godaly G et al. TLR- and CXCR1-dependent innate immunity: insights into the genetics of urinary tract infections. Eur J Clin Invest 2008; 38 (Suppl. 2): 12–20.
21. Ragnarsdóttir B, Samuelsson M, Gustafsson MC et al. Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria. J Infect Dis 2007; 196 (3): 475–84.
22. Wang H, Min G, Glockshuber R et al. Uropathogenic E. coli adhesin-induced host cell receptor conformational changes: implications in transmembrane signaling transduction. J Mol Biol 2009; 392 (2): 352–61.
23. Klumpp DJ, Rycyk MT, Chen MC et al. Uropathogenic Escherichia coli induces extrinsic and intrinsic cascades to initiate urothelial apoptosis. Infect Immun 2006; 74 (9): 5106–13.
24. Ingersoll MA, Kline KA, Nielsen HV, Hultgren SJ. G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity. Cell Microbiol 2008; 10 (12): 2568–78.
25. Dielubanza EJ, Schaeffer AJ. Urinary tract infections in women. Med Clin North Am 2011; 95 (1): 27–41.
26. Hannan TJ, Mysorekar IU, Hung CS et al. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 2010; 6 (8): e1001042.
27. Sivick KE, Mobley HL. Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect Immun 2010; 78 (2): 568–85.
28. Ingersoll MA, Albert ML. From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa. Mucosal Immunol 2013; 6 (6): 1041–53.
29. Fouts DE, Pieper R, Szpakowski S et al. Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury. J Transl Med 2012; 10: 174.
30. Siddiqui H, Nederbragt AJ, Lagesen K et al. Assessing diversity of the female urine microbiota by high throughput sequencing of 16S rDNA amplicons. BMC Microbiol 2011; 11: 244.
31. Sundén F, Hаkansson L, Ljunggren E, Wullt B. Bacterial interference-is deliberate colonization with Escherichia coli 83972 an alternative treatment for patients with recurrent urinary tract infection? Int J Antimicrob Agents 2006; 28 (Suppl. 1): S26–9.
32. Darouiche RO, Hull RA. Bacterial interference for prevention of urinary tract infection. Clin Infect Dis 2012; 55: 1400–7.
33. Zdziarski J, Brzuszkiewicz E, Wullt B et al. Host Imprints on Bacterial Genomes-Rapid, Divergent Evolution in Individual Patients. PLoS Pathog 2010; 6 (8).
34. Naber KG, Kogan M, Wagenlehner FME et al. How the microbiome is influenced by the therapy of urological diseases: standard versus alternative approaches. Clin Phytoscience 2017; 3: 8.
35. Ivanov D, Abramov-Sommariva D, Moritz K et al. An open label, non-controlled, multicentre, interventional trial to investigate the safety and efficacy of Canephron® N in the management of uncomplicated urinary tract infections (uUTIs). Clin Phytoscience 2015; 1: 7.
36. Gessner A. The influence of urologic therapeutics on the microbiome in an experimental model” in “How the microbiome is influenced by the therapy of urological diseases: standard vs. alternative approaches”. Munich: 31st Annual EAU Congress; 2016.
2. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon 2003; 49 (2): 71–82.
3. Jones CH, Pinkner JS, Roth R et al. FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. Proc Natl Acad Sci USA 1995; 92 (6): 2081–5.
4. Zhou G, Mo WJ, Sebbel P et al. Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. J Cell Sci 2001; 114 (Pt. 22): 4095–103.
5. Xie B, Zhou G, Chan SY et al. Distinct glycan structures of uroplakins Ia and Ib: structural basis for the selective binding of FimH adhesin to uroplakin Ia. J Biol Chem 2006; 281 (21): 14644–53.
6. Martinez JJ, Mulvey MA, Schilling JD et al. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 2000; 19 (12): 2803–12.
7. Rosen DA, Pinkner JS, Walker JN et al. Molecular variations in Klebsiella pneumoniae and Escherichia coli FimH affect function and pathogenesis in the urinary tract. Infect Immun 2008; 76 (7): 3346–56.
8. Martinez JJ, Mulvey MA, Schilling JD et al. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 2000; 19 (12): 2803–12.
9. Dhakal BK, Mulvey MA. Uropathogenic Escherichia coli invades host cells via an HDAC6-modulated microtubule-dependent pathway. J Biol Chem 2009; 284 (1): 446–54.
10. Justice SS, Hung C, Theriot JA et al. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci USA 2004; 101 (5): 1333–8.
11. Rosen DA, Pinkner JS, Jones JM et al. Utilization of an intracellular bacterial community pathway in Klebsiella pneumoniae urinary tract infection and the effects of FimK on type 1 pilus expression. Infect Immun 2008; 76 (7): 3337–45.
12. Mysorekar IU, Hultgren SJ. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci USA 2006; 103 (38): 14170–5.
13. Kau AL, Martin SM, Lyon W et al. Enterococcus faecalis tropism for the kidneys in the urinary tract of C57BL/6J mice. Infect Immun 2005; 73 (4): 2461–8.
14. Kline KA, Ingersoll MA, Nielsen HV et al. Characterization of a novel murine model of Staphylococcus saprophyticus urinary tract infection reveals roles for Ssp and SdrI in virulence. Infect Immun 2010; 78 (5): 1943–51.
15. Nielubowicz GR, Mobley HL. Host-pathogen interactions in urinary tract infection. Nat Rev Urol 2010; 7 (8): 430–41.
16. Sobel JD, Fisher JF, Kauffman CA, Newman CA. Candida urinary tract infections – epidemiology. Clin Infect Dis 2011; 52 (Suppl. 6): S433–6.
17. Tsai PW, Yang CY, Chang HT, Lan CY. Human antimicrobial peptide LL-37 inhibits adhesion of Candida albicans by interacting with yeast cell-wall carbohydrates. PLoS One 2011; 6 (3): e17755.
18. Yin X, Hou T, Liu Y et al. Association of Toll-like receptor 4 gene polymorphism and expression with urinary tract infection types in adults. PLoS One 2010; 5 (12): e14223.
19. Fischer H, Yamamoto M, Akira S et al. Mechanism of pathogen-specific TLR4 activation in the mucosa: fimbriae, recognition receptors and adaptor protein selection. Eur J Immunol 2006; 36 (2): 267–77.
20. Ragnarsdоttir B, Fischer H, Godaly G et al. TLR- and CXCR1-dependent innate immunity: insights into the genetics of urinary tract infections. Eur J Clin Invest 2008; 38 (Suppl. 2): 12–20.
21. Ragnarsdóttir B, Samuelsson M, Gustafsson MC et al. Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria. J Infect Dis 2007; 196 (3): 475–84.
22. Wang H, Min G, Glockshuber R et al. Uropathogenic E. coli adhesin-induced host cell receptor conformational changes: implications in transmembrane signaling transduction. J Mol Biol 2009; 392 (2): 352–61.
23. Klumpp DJ, Rycyk MT, Chen MC et al. Uropathogenic Escherichia coli induces extrinsic and intrinsic cascades to initiate urothelial apoptosis. Infect Immun 2006; 74 (9): 5106–13.
24. Ingersoll MA, Kline KA, Nielsen HV, Hultgren SJ. G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity. Cell Microbiol 2008; 10 (12): 2568–78.
25. Dielubanza EJ, Schaeffer AJ. Urinary tract infections in women. Med Clin North Am 2011; 95 (1): 27–41.
26. Hannan TJ, Mysorekar IU, Hung CS et al. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 2010; 6 (8): e1001042.
27. Sivick KE, Mobley HL. Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect Immun 2010; 78 (2): 568–85.
28. Ingersoll MA, Albert ML. From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa. Mucosal Immunol 2013; 6 (6): 1041–53.
29. Fouts DE, Pieper R, Szpakowski S et al. Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury. J Transl Med 2012; 10: 174.
30. Siddiqui H, Nederbragt AJ, Lagesen K et al. Assessing diversity of the female urine microbiota by high throughput sequencing of 16S rDNA amplicons. BMC Microbiol 2011; 11: 244.
31. Sundén F, Hаkansson L, Ljunggren E, Wullt B. Bacterial interference-is deliberate colonization with Escherichia coli 83972 an alternative treatment for patients with recurrent urinary tract infection? Int J Antimicrob Agents 2006; 28 (Suppl. 1): S26–9.
32. Darouiche RO, Hull RA. Bacterial interference for prevention of urinary tract infection. Clin Infect Dis 2012; 55: 1400–7.
33. Zdziarski J, Brzuszkiewicz E, Wullt B et al. Host Imprints on Bacterial Genomes-Rapid, Divergent Evolution in Individual Patients. PLoS Pathog 2010; 6 (8).
34. Naber KG, Kogan M, Wagenlehner FME et al. How the microbiome is influenced by the therapy of urological diseases: standard versus alternative approaches. Clin Phytoscience 2017; 3: 8.
35. Ivanov D, Abramov-Sommariva D, Moritz K et al. An open label, non-controlled, multicentre, interventional trial to investigate the safety and efficacy of Canephron® N in the management of uncomplicated urinary tract infections (uUTIs). Clin Phytoscience 2015; 1: 7.
36. Gessner A. The influence of urologic therapeutics on the microbiome in an experimental model” in “How the microbiome is influenced by the therapy of urological diseases: standard vs. alternative approaches”. Munich: 31st Annual EAU Congress; 2016.
________________________________________________
2. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon 2003; 49 (2): 71–82.
3. Jones CH, Pinkner JS, Roth R et al. FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. Proc Natl Acad Sci USA 1995; 92 (6): 2081–5.
4. Zhou G, Mo WJ, Sebbel P et al. Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. J Cell Sci 2001; 114 (Pt. 22): 4095–103.
5. Xie B, Zhou G, Chan SY et al. Distinct glycan structures of uroplakins Ia and Ib: structural basis for the selective binding of FimH adhesin to uroplakin Ia. J Biol Chem 2006; 281 (21): 14644–53.
6. Martinez JJ, Mulvey MA, Schilling JD et al. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 2000; 19 (12): 2803–12.
7. Rosen DA, Pinkner JS, Walker JN et al. Molecular variations in Klebsiella pneumoniae and Escherichia coli FimH affect function and pathogenesis in the urinary tract. Infect Immun 2008; 76 (7): 3346–56.
8. Martinez JJ, Mulvey MA, Schilling JD et al. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 2000; 19 (12): 2803–12.
9. Dhakal BK, Mulvey MA. Uropathogenic Escherichia coli invades host cells via an HDAC6-modulated microtubule-dependent pathway. J Biol Chem 2009; 284 (1): 446–54.
10. Justice SS, Hung C, Theriot JA et al. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci USA 2004; 101 (5): 1333–8.
11. Rosen DA, Pinkner JS, Jones JM et al. Utilization of an intracellular bacterial community pathway in Klebsiella pneumoniae urinary tract infection and the effects of FimK on type 1 pilus expression. Infect Immun 2008; 76 (7): 3337–45.
12. Mysorekar IU, Hultgren SJ. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci USA 2006; 103 (38): 14170–5.
13. Kau AL, Martin SM, Lyon W et al. Enterococcus faecalis tropism for the kidneys in the urinary tract of C57BL/6J mice. Infect Immun 2005; 73 (4): 2461–8.
14. Kline KA, Ingersoll MA, Nielsen HV et al. Characterization of a novel murine model of Staphylococcus saprophyticus urinary tract infection reveals roles for Ssp and SdrI in virulence. Infect Immun 2010; 78 (5): 1943–51.
15. Nielubowicz GR, Mobley HL. Host-pathogen interactions in urinary tract infection. Nat Rev Urol 2010; 7 (8): 430–41.
16. Sobel JD, Fisher JF, Kauffman CA, Newman CA. Candida urinary tract infections – epidemiology. Clin Infect Dis 2011; 52 (Suppl. 6): S433–6.
17. Tsai PW, Yang CY, Chang HT, Lan CY. Human antimicrobial peptide LL-37 inhibits adhesion of Candida albicans by interacting with yeast cell-wall carbohydrates. PLoS One 2011; 6 (3): e17755.
18. Yin X, Hou T, Liu Y et al. Association of Toll-like receptor 4 gene polymorphism and expression with urinary tract infection types in adults. PLoS One 2010; 5 (12): e14223.
19. Fischer H, Yamamoto M, Akira S et al. Mechanism of pathogen-specific TLR4 activation in the mucosa: fimbriae, recognition receptors and adaptor protein selection. Eur J Immunol 2006; 36 (2): 267–77.
20. Ragnarsdоttir B, Fischer H, Godaly G et al. TLR- and CXCR1-dependent innate immunity: insights into the genetics of urinary tract infections. Eur J Clin Invest 2008; 38 (Suppl. 2): 12–20.
21. Ragnarsdóttir B, Samuelsson M, Gustafsson MC et al. Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria. J Infect Dis 2007; 196 (3): 475–84.
22. Wang H, Min G, Glockshuber R et al. Uropathogenic E. coli adhesin-induced host cell receptor conformational changes: implications in transmembrane signaling transduction. J Mol Biol 2009; 392 (2): 352–61.
23. Klumpp DJ, Rycyk MT, Chen MC et al. Uropathogenic Escherichia coli induces extrinsic and intrinsic cascades to initiate urothelial apoptosis. Infect Immun 2006; 74 (9): 5106–13.
24. Ingersoll MA, Kline KA, Nielsen HV, Hultgren SJ. G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity. Cell Microbiol 2008; 10 (12): 2568–78.
25. Dielubanza EJ, Schaeffer AJ. Urinary tract infections in women. Med Clin North Am 2011; 95 (1): 27–41.
26. Hannan TJ, Mysorekar IU, Hung CS et al. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 2010; 6 (8): e1001042.
27. Sivick KE, Mobley HL. Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect Immun 2010; 78 (2): 568–85.
28. Ingersoll MA, Albert ML. From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa. Mucosal Immunol 2013; 6 (6): 1041–53.
29. Fouts DE, Pieper R, Szpakowski S et al. Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury. J Transl Med 2012; 10: 174.
30. Siddiqui H, Nederbragt AJ, Lagesen K et al. Assessing diversity of the female urine microbiota by high throughput sequencing of 16S rDNA amplicons. BMC Microbiol 2011; 11: 244.
31. Sundén F, Hаkansson L, Ljunggren E, Wullt B. Bacterial interference-is deliberate colonization with Escherichia coli 83972 an alternative treatment for patients with recurrent urinary tract infection? Int J Antimicrob Agents 2006; 28 (Suppl. 1): S26–9.
32. Darouiche RO, Hull RA. Bacterial interference for prevention of urinary tract infection. Clin Infect Dis 2012; 55: 1400–7.
33. Zdziarski J, Brzuszkiewicz E, Wullt B et al. Host Imprints on Bacterial Genomes-Rapid, Divergent Evolution in Individual Patients. PLoS Pathog 2010; 6 (8).
34. Naber KG, Kogan M, Wagenlehner FME et al. How the microbiome is influenced by the therapy of urological diseases: standard versus alternative approaches. Clin Phytoscience 2017; 3: 8.
35. Ivanov D, Abramov-Sommariva D, Moritz K et al. An open label, non-controlled, multicentre, interventional trial to investigate the safety and efficacy of Canephron® N in the management of uncomplicated urinary tract infections (uUTIs). Clin Phytoscience 2015; 1: 7.
36. Gessner A. The influence of urologic therapeutics on the microbiome in an experimental model” in “How the microbiome is influenced by the therapy of urological diseases: standard vs. alternative approaches”. Munich: 31st Annual EAU Congress; 2016.
Авторы
И.Н.Захарова*, Э.Б.Мумладзе, Е.Б.Мачнева, А.Н.Касьянова
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*zakharova-rmapo@yandex.ru
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125995, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*zakharova-rmapo@yandex.ru
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*zakharova-rmapo@yandex.ru
________________________________________________
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125995, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*zakharova-rmapo@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.